Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM4QHZS)

Drug Name

BMS-986177 Drug Info

Synonyms

Milvexian; UNII-0W79NDQ608; Milvexian (USAN); Milvexian [USAN]; BMS 986177; JNJ-70033093; 1802425-99-5; CHEMBL4112929; SCHEMBL16982989; WHO 11401; D11802; (5R,9S)-9-(4-(5-Chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl)-6-oxopyrimidin-1(6H)-yl)-21-(difluoromethyl)-5-methyl-21H-3-aza-1(4,2)-pyridina-2(5,4)-pyrazolacyclonaphan-4-one; (9R,13S)-13-{4-[5-chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl]-6-oxo-1,6-dihydropyrimidin-1-yl}-3-(difluoromethyl)-9-methyl-3,4,7,15-tetraazatricyclo[12.3.1.02,6]octadeca-1(18),2(6),4,14,16-pentaen-8-one; 11,15-Metheno-15H-pyrazolo(4,3-b)(1,7)diazacyclotetradecin-5(6H)-one, 10-(4-(5-chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl)-6-oxo-1(6H)-pyrimidinyl)-1-(difluoromethyl)-1,4,7,8,9,10-hexahydro-6-methyl-, (6R,10S)-2

Indication

Disease Entry	ICD 11	Status	REF
Cerebral ischemia	8B11	Phase 2	[1]
Ischemic stroke	8B11.5Z	Phase 2	[2]
Thrombosis	DB61-GB90	Phase 1	[3]

Cross-matching ID

PubChem CID: 118277544
CAS Number: CAS 1802425-99-5
TTD Drug ID: DM4QHZS

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Factor XI messenger RNA (F11 mRNA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
ISIS-FXI	DMHETPI	Coagulation defect	3B10.0	Phase 2	[5]
IONIS-416858	DM5F0QY	Thrombosis	DB61-GB90	Phase 2	[6]
alpha-ketothiazole analogue 36	DMN2I3P	Alzheimer disease	8A20	Clinical trial	[7]
FXI-AS1	DMAZ1NW	Thrombosis	DB61-GB90	Investigative	[8]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Factor XI messenger RNA (F11 mRNA)	TTDM4ZU	FA11_HUMAN	Inhibitor	[4]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT03766581) A Study on BMS-986177 for the Prevention of a Stroke in Patients Receiving Aspirin and Clopidogrel (AXIOMATIC-SSP). U.S. National Institutes of Health.
2	ClinicalTrials.gov (NCT03766581) A Study on BMS-986177 for the Prevention of a Stroke in Patients Receiving Aspirin and Clopidogrel (AXIOMATIC-SSP). U.S. National Institutes of Health.
3	ClinicalTrials.gov (NCT03224260) To Evaluate the Safety and Pharmacokinetics of BMS-986177 in Healthy Japanese Participants. U.S. National Institutes of Health.
4	Discovery methods of coagulation-inhibiting drugs. Expert Opin Drug Discov. 2017 Dec;12(12):1195-1205.
5	Clinical pipeline report, company report or official report of ISIS Pharmaceuticals (2011).
6	Clinical pipeline report, company report or official report of Ionis Pharmaceuticals.
7	Inhibitors of proteases and amide hydrolases that employ an alpha-ketoheterocycle as a key enabling functionality. Bioorg Med Chem. 2008 Feb 15;16(4):1562-95.
8	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2360).